Top

Published in:

Open Access 01-09-2020 | Magnetic Resonance Imaging | Review Article

¹⁸F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature

Authors: Laura Evangelista, Ilaria Ravelli, Fabio Magnani, Maurizio Iacobone, Chiara Giraudo, Valentina Camozzi, Alessandro Spimpolo, Diego Cecchin

Published in: Annals of Nuclear Medicine | Issue 9/2020

Abstract

The aims of the present systematic review were to: (1) assess the role of ¹⁸F-fluorocholine (FCH) positron emission tomography (PET) with computed tomography (CT) and PET with magnetic resonance imaging (MRI) in patients with biochemically known hyperparathyroidism; (2) compare the diagnostic performance of FCH PET/CT or PET/MRI with conventional morphological and functional imaging. A literature search until December 2019 was performed in the PubMed, Scopus and Web of Science databases, using the terms “choline” AND “PET” AND “hyperparathyroidism”. The search was conducted with and without the addition of filters (e.g., language: English only; type of article: original article; subjects: humans only) and selecting only articles published in the last 5 years. Twenty-three articles and 1112 patients were considered. Different FCH PET/CT acquisition protocols were adopted across the studies, using dynamic, early or delayed scans. FCH PET/CT proved more accurate than ultrasonography (US) or 99mTc-sestamibi single-photon emission tomography (SPET). PET/MRI also seemed to be more accurate than MRI alone in detecting benign parathyroid lesions. FCH PET/CT is more accurate than conventional morphological and functional imaging modalities (US or SPET) for the detection of benign parathyroid lesions. It could, therefore, be a reliable tool in both primary and recurrent hyperparathyroidism.

Hindié E, Ugur O, Fuster D, O’Doherty M, Grassetto G, Ureña P, Kettle A, Gulec SA, Pons F, Rubello D. Parathyroid Task Group of the EANM, 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009;36:1201–16. https://doi.org/10.1007/s00259-009-1131-z.CrossRefPubMed

Delellis RA, Mazzaglia P, Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med. 2008;132:1251–62. https://doi.org/10.1043/1543-2165(2008)132%5b1251:PHACP%5d2.0.CO;2.CrossRefPubMed

Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31:916–23. https://doi.org/10.1007/s00268-006-0837-3.CrossRefPubMed

Amadou C, Bera G, Ezziane M, Chami L, Delbot T, Rouxel A, Leban M, Herve G, Menegaux F, Leenhardt L, Kas A, Trésallet C, Ghander C, Lussey-Lepoutre C. ¹⁸F-fluorocholine PET/CT and parathyroid 4D computed tomography for primary hyperparathyroidism: the challenge of reoperative patients. World J Surg. 2019;43:1232–42. https://doi.org/10.1007/s00268-019-04910-6.CrossRefPubMed

Reid LJ, Muthukrishnan B, Patel D, Seckl JR, Gibb FW. Predictors of nephrolithiasis, osteoporosis, and mortality in primary hyperparathyroidism. J Clin Endocrinol Metab. 2019;104:3692–700. https://doi.org/10.1210/jc.2018-02483.CrossRefPubMed

Collier A, Ghosh S, Nowell S, Clark D. Increased mortality in patients with primary hyperparathyroidism: does surgery make a difference? Endocr Pract. 2019;25:335–9. https://doi.org/10.4158/EP-2018-0407.CrossRefPubMed

Ciappuccini R, Morera J, Pascal P, Rame J-P, Heutte N, Aide N, Babin E, Reznik Y, Bardet S. Dual-phase 99mTc sestamibi scintigraphy with neck and thorax SPECT/CT in primary hyperparathyroidism: a single-institution experience. Clin Nucl Med. 2012;37:223–8. https://doi.org/10.1097/RLU.0b013e31823362e5.CrossRefPubMed

Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, Rubello D. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305–14. https://doi.org/10.1097/RLU.0b013e3182867f3c.CrossRefPubMed

Quak E, Lheureux S, Reznik Y, Bardet S, Aide N. F18-choline, a novel PET tracer for parathyroid adenoma? J Clin Endocrinol Metab. 2013;98:3111–2. https://doi.org/10.1210/jc.2013-2084.CrossRefPubMed

10.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. https://doi.org/10.1136/bmj.327.7414.557.CrossRefPubMedPubMedCentral

11.

Moher D, Liberati A, Tetzlaff J, Altman DG, DPRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. https://doi.org/10.7326/0003-4819-151-4-200908180-00135.CrossRefPubMed

12.

Michaud L, Burgess A, Huchet V, Lefèvre M, Tassart M, Ohnona J, Kerrou K, Balogova S, Talbot J-N, Périé S. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab. 2014;99:4531–6. https://doi.org/10.1210/jc.2014-2821.CrossRefPubMed

13.

Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, Lefèvre M, Tassart M, Montravers F, Périé S, Talbot J-N. A pilot comparison of ¹⁸F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of. Medicine (Baltimore). 2015;94:e1701. https://doi.org/10.1097/MD.0000000000001701.CrossRef

14.

Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh Q-Y, Vriens MR, de Keizer B, Hope TA, Glastonbury CM, Pampaloni MH, Suh I. ¹⁸F fluorocholine PET/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: a prospective pilot study. Radiology. 2017;284:460–7. https://doi.org/10.1148/radiol.2016160768.CrossRefPubMed

15.

Prabhu M, Kumari G, Damle NA, Arora G, Kumar P, Kumar R, Tripathi M, Bal C, Khadgawat R, Kumar C, Agarwal S. Assessment of the role of early dynamic PET/CT with ¹⁸F-fluorocholine in detection of parathyroid lesions in patients with primary hyperparathyroidism. Nucl Med Commun. 2018;39:1190–6. https://doi.org/10.1097/MNM.0000000000000924.CrossRefPubMed

16.

Kluijfhout WP, Vorselaars WMCM, van den Berk SAM, Vriens MR, Borel Rinkes IHM, Valk GD, van Dalen T, de Klerk JMH, de Keizer B. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl Med Commun. 2016;37:1246–52. https://doi.org/10.1097/MNM.0000000000000595.CrossRefPubMed

17.

Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, de Raucourt D, Grellard J-M, Licaj I, Bardet S, Reznik Y, Clarisse B, Aide N. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging. 2018;45:658–66. https://doi.org/10.1007/s00259-017-3911-1.CrossRefPubMed

18.

Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, Berdelou A, Hadoux J, Hescot S, Remy H, Baudin E, Schlumberger M, Deandreis D. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of ¹⁸F-Fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2018;45:1772–80. https://doi.org/10.1007/s00259-018-4018-z.CrossRefPubMed

19.

Huber GF, Hüllner M, Schmid C, Brunner A, Sah B, Vetter D, Kaufmann PA, von Schulthess GK. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Eur Radiol. 2018;28:2700–7. https://doi.org/10.1007/s00330-017-5190-4.CrossRefPubMed

20.

Araz M, Soydal Ç, Özkan E, Kir MK, İbiş E, Güllü S, Erdoğan MF, Emral R, Küçük ÖN. The efficacy of fluorine-18-choline PET/CT in comparison with 99mTc-MIBI SPECT/CT in the localization of a hyperfunctioning parathyroid gland in primary hyperparathyroidism. Nucl Med Commun. 2018;39:989–94. https://doi.org/10.1097/MNM.0000000000000899.CrossRefPubMed

21.

Piccardo A, Trimboli P, Rutigliani M, Puntoni M, Foppiani L, Bacigalupo L, Crescenzi A, Bottoni G, Treglia G, Paparo F, Del Monte P, Lanata M, Paone G, Ferrarazzo G, Catrambone U, Arlandini A, Ceriani L, Cabria M, Giovanella L. Additional value of integrated ¹⁸F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. Eur J Nucl Med Mol Imaging. 2019;46:766–75. https://doi.org/10.1007/s00259-018-4147-4.CrossRefPubMed

22.

Zajíčková K, Zogala D, Kubinyi J. Parathyroid imaging by (18)F-fluorocholine PET/CT in patients with primary hyperparathyroidism and inconclusive conventional methods: clinico-pathological correlations. Physiol Res. 2018;67:S551–7. https://doi.org/10.33549/physiolres.934029.CrossRefPubMed

23.

Fischli S, Suter-Widmer I, Nguyen BT, Müller W, Metzger J, Strobel K, Grünig H, Henzen C. The Significance of 18F-fluorocholine-PET/CT as localizing imaging technique in patients with primary hyperparathyroidism and negative conventional imaging. Front Endocrinol (Lausanne). 2017;8:380. https://doi.org/10.3389/fendo.2017.00380.CrossRef

24.

Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J. ¹⁸F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging. 2014;41:2083–9. https://doi.org/10.1007/s00259-014-2837-0.CrossRefPubMed

25.

Rep S, Lezaic L, Kocjan T, Pfeifer M, Sever MJ, Simoncic U, Tomse P, Hocevar M. Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CT. Radiol Oncol. 2015;49:327–33. https://doi.org/10.1515/raon-2015-0016.CrossRefPubMedPubMedCentral

26.

Hocevar M, Lezaic L, Rep S, Zaletel K, Kocjan T, Sever MJ, Zgajnar J, Peric B. Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with ¹⁸F-Fluorocholine PET/CT. Eur J Surg Oncol. 2017;43:133–7. https://doi.org/10.1016/j.ejso.2016.09.016.CrossRefPubMed

27.

Rep S, Hocevar M, Vaupotic J, Zdesar U, Zaletel K, Lezaic L. ¹⁸F-choline PET/CT for parathyroid scintigraphy: significantly lower radiation exposure of patients in comparison to conventional nuclear medicine imaging approaches. J Radiol Prot. 2018;38:343–56. https://doi.org/10.1088/1361-6498/aaa86f.CrossRefPubMed

28.

Alharbi AA, Alshehri FM, Albatly AA, Sah B-R, Schmid C, Huber GF, Huellner MW. [¹⁸F]fluorocholine uptake of parathyroid adenoma is correlated with parathyroid hormone level. Mol Imaging Biol. 2018;20:857–67. https://doi.org/10.1007/s11307-018-1179-x.CrossRefPubMed

29.

Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, Tsybrovskyy O, Langsteger W, Pirich C. 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur. J. Nucl. Med. Mol. Imaging. 2018;45:1762–71. https://doi.org/10.1007/s00259-018-3980-9.CrossRefPubMedPubMedCentral

30.

Bossert I, Chytiris S, Hodolic M, Croce L, Mansi L, Chiovato L, Mariani G, Trifirò G. PETC/CT with 18F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J Endocrinol Invest. 2019;42:419–26. https://doi.org/10.1007/s40618-018-0931-z.CrossRefPubMed

31.

Christakis I, Khan S, Sadler GP, Gleeson FV, Bradley KM, Mihai R. 18Fluorocholine PET/CT scanning with arterial phase-enhanced CT is useful for persistent/recurrent primary hyperparathyroidism: first UK case series results. Ann R Coll Surg Engl. 2019;101:501–7. https://doi.org/10.1308/rcsann.2019.0059.CrossRefPubMedPubMedCentral

32.

Thanseer NTK, Parihar AS, Sood A, Bhadada SK, Dahiya D, Singh P, Mittal BR. Evaluation of recurrent parathyroid carcinoma: a new imaging tool in uncommon entity. World J Nucl Med. 2018;18:198–200. https://doi.org/10.4103/wjnm.WJNM_67_18.CrossRef

33.

Broos WAM, van der Zant FM, Knol RJJ, Wondergem M. Choline PET/CT in parathyroid imaging: a systematic review. Nucl Med Commun. 2019;40:96–105. https://doi.org/10.1097/MNM.0000000000000952.CrossRefPubMed

34.

Hansen BB, Hansen P, Nordberg CL, Boesen M. Imaging of the spine in cases of low back pain. Ugeskr Laeger. 2018;180(16):V06170475PubMed

35.

Fukumoto M. Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin. Ann Nucl Med. 2004;18:79–95. https://doi.org/10.1007/bf02985098.CrossRefPubMed

36.

Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400–19. https://doi.org/10.1053/j.semnuclmed.2007.08.004.CrossRefPubMed

37.

Ishizuka T, Kajita K, Kamikubo K, Komaki T, Miura K, Nagao S, Nozawa Y. Phospholipid/Ca2 + -dependent protein kinase activity in human parathyroid adenoma. Endocrinol Jpn. 1987;34:965–8. https://doi.org/10.1507/endocrj1954.34.965.CrossRefPubMed

38.

Kim S-J, Lee S-W, Jeong SY, Pak K, Kim K. Diagnostic performance of F-18 fluorocholine PET/CT for parathyroid localization in hyperparathyroidism: a systematic review and meta-analysis. Horm Cancer. 2018;9:440–7. https://doi.org/10.1007/s12672-018-0347-4.CrossRefPubMed

39.

Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, Giovanella L. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:751–65. https://doi.org/10.1007/s00259-018-4123-z.CrossRefPubMed

40.

Boccalatte LA, Higuera F, Gómez NL, de la Torre AY, Mazzaro EL, Galich AM, Collaud C, Figari MF. Usefulness of 18F-fluorocholine positron emission tomography-computed tomography in locating lesions in hyperparathyroidism: a systematic review. JAMA Otolaryngol Head Neck Surg. 2019. https://doi.org/10.1001/jamaoto.2019.0574.CrossRefPubMed

41.

Johnson NA, Tublin ME, Ogilvie JB. Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. AJR Am J Roentgenol. 2007;188:1706–15. https://doi.org/10.2214/AJR.06.0938.CrossRefPubMed

42.

Yildiz S, Aralasmak A, Yetis H, Kilicarslan R, Sharifov R, Alkan A, Toprak H. MRI findings and utility of DWI in the evaluation of solid parathyroid lesions. Radiol Med. 2019;124:360–7. https://doi.org/10.1007/s11547-018-0970-8.CrossRefPubMed

43.

Starker LF, Mahajan A, Bjorklund P, Sze G, Udelsman R, Carling T. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol. 2011;18:1723–8.CrossRefPubMed

44.

Mekel M, Linder R, Bishara B, Kluger Y, Bar-On O, Fischer D. 4-dimensional computed tomography for localization of parathyroid adenoma. Harefuah. 2013;152:710–2.PubMed

45.

Hamidi M, Sullivan M, Hunter G, Hamberg L, Cho NL, Gawande AA, et al. 4D-CT is superior to ultrasound and sestamibi for localizing recurrent parathyroid disease. Ann Surg Oncol. 2018;25(5):1403–9.CrossRefPubMed

46.

Tian Y, Tanny ST, Einsiedel P, Lichtenstein M, Stella DL, Phal PM, et al. Four-dimensional computed tomography: clinical impact for patients with primary hyperparathyroidism. Ann Surg Oncol. 2018;25:117–21.CrossRefPubMed

47.

Argirò R, Diacinti D, Sacconi B, Iannarelli A, Diacinti D, Cipriani C, Pisani D, Romagnoli E, Biffoni M, Di Gioia C, Pepe J, Bezzi M, Letizia C, Minisola S, Catalano C. Diagnostic accuracy of 3T magnetic resonance imaging in the preoperative localisation of parathyroid adenomas: comparison with ultrasound and 99mTc-sestamibi scans. Eur Radiol. 2018;28:4900–8. https://doi.org/10.1007/s00330-018-5437-8.CrossRefPubMed

48.

Ozturk M, Polat AV, Celenk C, Elmali M, Kir S, Polat C. The diagnostic value of 4D MRI at 3T for the localization of parathyroid adenomas. Eur J Radiol. 2019;112:207–13. https://doi.org/10.1016/j.ejrad.2019.01.022.CrossRefPubMed

Title: 18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature
Authors: Laura Evangelista
Ilaria Ravelli
Fabio Magnani
Maurizio Iacobone
Chiara Giraudo
Valentina Camozzi
Alessandro Spimpolo
Diego Cecchin
Publication date: 01-09-2020
Publisher: Springer Singapore
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Computed Tomography
Computed Tomography
Hyperparathyroidism
Positron Emission Tomography
Scintigraphy
Published in: Annals of Nuclear Medicine / Issue 9/2020
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-020-01507-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

¹⁸F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2020

18F-FDG uptake as a predictive factor for progressive aortic enlargement in aortic dissection

Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer

High detection sensitivity and reliable morphological correlation of PET with a silicon photomultiplier for primary tongue squamous cell carcinoma

Visualization of translocator protein (18 kDa) (TSPO) in the retina of diabetic retinopathy rats using fluorine-18-DPA-714

A method to measure the extent of myocardial ischemia and steal with SPECT myocardial blood flow quantitation

Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation